Efficacy and Safety of Mepolizumab in Eosinophilic COPD: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Key Points

• To evaluate the efficacy and safety of mepolizumab in treating eosinophilic COPD.
• Systematic review and meta-analysis of randomized controlled trials
• Focused on the effects of mepolizumab on exacerbation rates and safety
• Included data on symptom-free periods and adverse events
• Mepolizumab reduced time to first moderate or severe exacerbation significantly (exact rates not provided)
• Prolonged symptom-free periods were noted in treated individuals
• No increase in adverse events reported compared to control